Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03481530 · ClinicalTrials.gov registry record
Role of CGMS Usage in Predicting Risk for Hypoglycemia
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 41
- Enrollment target
NCT03481530: Completed study, sponsored by University of Minnesota.
NCT03481530 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03481530 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 41 participants
- Enrollment target
Study Summary
This is a clinical study to examine rates hypoglycemia (self-report, EHR review, and review of values from a FDA approved continuous glucose monitoring system (CGMS)). Subjects will wear either blinded or unblinded CGMS. This is a 1:1 assignment with one group (50%) wearing 1 unblinded/1 blinded CGMS and the other group 50% wearing 2 blinded CGMS. The assignment will be computer based in a random fashion. Participants will continue with their usual diabetes management and glycemic monitoring profile as per usual. Those assigned to an unblinded CGMS can use the CGMS to manage their glucose levels at their own discretion. Individuals recruited will be those Type 2 diabetes who are deemed to be at high risk for hypoglycemia or low risk for hypoglycemia from a point score system established in an affiliated study.
Primary Outcome
Overall rate
Interventions
- DEVICE Continuing Glucose Monitor System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2025-09-30 |
What the finished NCT03481530 record still lists
NCT03481530 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 41 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Continuing Glucose Monitor System is the first listed.
NCT03481530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03481530 about?
NCT03481530 is a clinical study titled "Role of CGMS Usage in Predicting Risk for Hypoglycemia". This is a clinical study to examine rates hypoglycemia (self-report, EHR review, and review of values from a FDA approved continuous glucose monitoring system (CGMS)). Subjects will wear either blinded or unblinded CGMS. This is a 1:1 assignment with one group (50%) wearing 1 unblinded/1 blinded CGM...
What is the current status of trial NCT03481530?
This trial is currently completed. The enrollment target is 41 participants. The study started on 2018-10-01. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT03481530?
The interventions under investigation include: Continuing Glucose Monitor System (DEVICE).
Who is sponsoring clinical trial NCT03481530?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI